Strs Ohio Raises Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Strs Ohio boosted its stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 270.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 87,500 shares of the biotechnology company’s stock after acquiring an additional 63,900 shares during the period. Strs Ohio’s holdings in Aldeyra Therapeutics were worth $307,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Prime Capital Investment Advisors LLC acquired a new position in shares of Aldeyra Therapeutics in the fourth quarter worth $35,000. SG Americas Securities LLC acquired a new position in Aldeyra Therapeutics in the 4th quarter valued at about $39,000. Aigen Investment Management LP purchased a new position in Aldeyra Therapeutics in the 3rd quarter valued at about $80,000. Pale Fire Capital SE acquired a new stake in shares of Aldeyra Therapeutics during the 3rd quarter worth about $98,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Aldeyra Therapeutics during the 3rd quarter worth about $124,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Insider Activity at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc bought 8,374 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was purchased at an average price of $3.25 per share, with a total value of $27,215.50. Following the transaction, the insider now owns 8,601,960 shares in the company, valued at $27,956,370. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Bruce Greenberg sold 13,201 shares of Aldeyra Therapeutics stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $3.41, for a total transaction of $45,015.41. Following the sale, the insider now owns 120,699 shares in the company, valued at $411,583.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Perceptive Advisors Llc bought 8,374 shares of Aldeyra Therapeutics stock in a transaction dated Monday, April 1st. The shares were purchased at an average cost of $3.25 per share, for a total transaction of $27,215.50. Following the completion of the transaction, the insider now owns 8,601,960 shares of the company’s stock, valued at approximately $27,956,370. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 355,933 shares of company stock worth $1,473,245. 7.30% of the stock is owned by insiders.

Analysts Set New Price Targets

ALDX has been the topic of several recent analyst reports. Oppenheimer raised shares of Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research note on Wednesday, April 3rd. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Tuesday, April 2nd. Finally, StockNews.com raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 29th.

Aldeyra Therapeutics Stock Performance

ALDX opened at $4.05 on Tuesday. Aldeyra Therapeutics, Inc has a 1 year low of $1.42 and a 1 year high of $11.97. The company’s 50 day simple moving average is $3.65 and its 200 day simple moving average is $3.16. The stock has a market capitalization of $240.61 million, a PE ratio of -6.33 and a beta of 1.51.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.13. As a group, sell-side analysts expect that Aldeyra Therapeutics, Inc will post -0.14 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.